The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10 (b) and 20 (a) of the Securities ...

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Capricor Therapeutics Inc. and its CEO overhyped regulatory approval odds for its cell therapy to treat a serious heart ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) ...

US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency’s new leadership ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

Find the latest on short interest, settlement dates, average share volume, and days to cover for Capricor Therapeutics, Inc. Common Stock (CAPR) at Nasdaq.com.